International study supports dupilumab for treatment of moderate-to-severe asthma in children

In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.

Weigh risks, plan ahead prior to gathering for the holidays

Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers.

Treating children with cancer requires a strong blood supply; donations critically needed

VUMC awarded CDC funding to combat antimicrobial resistance, infectious diseases

Vanderbilt has partnered with the CDC to combat the crisis of antimicrobial resistance and other healthcare threats through a newly created Global Action in Healthcare Network (GAIHN).

Potential Rett syndrome drug shows promising results in phase 3 trial

A potential first-of-its-kind drug to treat the symptoms of Rett syndrome received positive top-line results from a phase 3 trial led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety.

VUMC mourns loss of pediatric immunology expert Lawton

Alexander R. “Sandy” Lawton III, MD, emeritus professor of Pediatrics, died earlier this fall at 82.